Drugs / Lyophilized sterile fecal filtrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03806803 | Mar 2019 → Mar 2024 | Clostridium difficile colitis | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT03353506 | Feb 2018 → Jun 2019 | Clostridium difficile colitis, enterocolitis | Dina Kao | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lyophilized sterile fecal filtrate | “Lyophilized sterile fecal filtrate” NCT03353506 ↗ |
| Known as | LSFF | “This study aims to determine whether lyophilised sterile faecal filtrate (LSFF), free of live bacteria, is non-inferior to lyophilised donor stool (LFMT) in efficacy.” PMID 40997843 ↗ Sep 2025 |
| Modality | Other / unclassified | “filtered fecal slurry, free of any live bacteria” NCT03806803 ↗ |
| Route | Oral | “receive either LSFF or LFMT by capsules” NCT03353506 ↗ |